First-of-its-kind consortium made up of healthcare industry leaders aims to establish standards for RFID use
(March 1, 2021) – International technology group SCHOTT AG, today announced that it has joined DoseID, the first member driven industry consortium for the use of radio-frequency identification (RFID) technology in the healthcare space. DoseID consists of industry innovators who are committed to increasing the interoperability, quality and performance of RFID-tagged products as they move through the pharmaceutical supply chain from manufacturer to patient.
As a leading pharmaceutical packaging supplier, SCHOTT supports the integration of RFID technology in primary packaging products. These approaches will allow to optimize the supply chain at the fill- and finish process as well as gain efficiencies in hospitals, help with inventory management, and reduce health care professional’s workload through digitalization.
The DoseID RFID tag certification will be provided by Auburn University RFID Lab’s ARC Program. This ensures that parties not only meet the standards set by the consortium, but that the established standards meet the needs of industry players including pharmaceutical manufacturers, 503b compounding pharmacies, pharmacy automation vendors, and inlay and tag manufacturers. Members of DoseID, which launched in August 2020, hail from other companies across the spectrum including Omnicell Inc., Sandoz, Baxter, Hikma, Leiters, Nephron Pharmaceuticals, Avery Dennison, Kit Check and CCL Healthcare.
“We believe the pharmaceutical industry will greatly benefit of RFID-tagged products and are looking forward to exchanging knowledge and insights with the consortium members,” said Mario Haas, Head of SBF Polymer Solutions at SCHOTT Pharmaceutical Systems.
DoseID takes serialization beyond Drug Supply Chain Security Act (DSCSA), from the unit of sale to the unit of use. It uniquely serializes every dose, container, or device to track each action taken upon it during its entire lifecycle and ensures RFID tagged drugs work in all downstream IT systems in hospitals and health systems. The organizations that make up DoseID collectively account for the majority of the existing RFID tagging market, positioning the consortium well to combat the challenges associated with unit level drug visibility. Some of the concepts of DoseID have already been shown to be successful, with more than 120 million tagged units in the field to-date and a recent pilot with the FDA associated with DSCSA compliance.
It is only with participation across the entire pharmaceutical supply chain that RFID unit-level medication tracking can achieve the DoseID goals of interoperability, reliable tag performance and complete and accurate data.
To learn more about SCHOTT visit schott.com/pharmaceutical. To learn more about DoseID, please visit doseid.com.
SCHOTT Press Contact:
SCHOTT AG
Joana Kornblum
Public Relations Manager
Tel.: +49 6131/66-4073
